Intellia Therapeutics Inc
NTLAHealthcare|Biotechnology|USA
$14.21
-1.23 (-7.99%)
Tangible Book
$5.16
Financials
Financial Snapshot
Market Cap
$1.99B
Enterprise Value
$295.5M
Revenue (TTM)
$66.1M
Net Income (TTM)
$-394.6M
Cash & Equivalents
—
Net Cash/Share
$1.98
Free Cash Flow (TTM)
$-363.6M
Operating CF (TTM)
$-363.2M
Debt/Equity
0.13
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$90.8M
Monthly Burn
$30.3M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $273.1M | $340.7M | $314.1M | $279.7M | $597.4M | $748.7M | $1.19B | $912.2M | $601.5M | $449.9M | $376.0M | |
| Operating Cash Flow | $36.1M | $-65.3M | $-61.3M | $-103.2M | $-49.9M | $-225.0M | $-333.3M | $-394.1M | $-348.9M | $-394.7M | $-363.2M | |
| Free Cash Flow | $29.9M | $-75.4M | $-67.6M | $-110.0M | $-53.5M | $-237.8M | $-391.7M | $-408.1M | $-354.7M | $-395.9M | $-363.6M | |
| Capital Expenditure | $-6.2M | $-10.1M | $-6.4M | $-6.8M | $-3.6M | $-12.8M | $-58.4M | $-14.0M | $-5.8M | $-1.1M | $-473.0K | |
| Financing Cash Flow | $167.3M | $143.0M | $40.2M | $76.4M | $371.8M | $736.7M | $583.0M | $130.3M | $185.7M | $131.5M | $165.1M |
R&D Spending
R&D (TTM)
$361.2M
R&D Intensity
546.5%
R&D Growth YoY
-7.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M | $66.1M | |
| R&D Expense | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | $388.9M | $361.2M | |
| R&D % of Revenue | 193.2% | 259.0% | 292.8% | 251.5% | 259.4% | 695.3% | 805.8% | 1199.4% | 805.7% | 574.6% | 546.5% | |
| SG&A | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | $119.8M | $125.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M | $66.1M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M | $66.1M | |
| R&D | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | $388.9M | $361.2M | |
| SG&A | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | $119.8M | $125.6M | |
| Operating Income | $-32.2M | $-69.6M | $-90.9M | $-106.4M | $-136.6M | $-267.9M | $-458.2M | $-515.3M | $-534.3M | $-441.0M | $-420.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-31.6M | $-67.5M | $-85.3M | $-99.5M | $-134.2M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | $-412.7M | $-394.6M | |
| Net Income | $-31.6M | $-67.5M | $-85.3M | $-99.5M | $-134.2M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | $-412.7M | $-394.6M | |
| EPS (Diluted) | -1.42 | -1.88 | -1.98 | -2.11 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | -3.54 | |
| EBITDA | $-31.1M | $-66.6M | $-86.4M | $-100.8M | $-130.3M | $-261.0M | $-450.6M | $-506.3M | $-524.0M | $-425.1M | $-405.1M | |
| Shares Out. (M) | 22.22 | 36.01 | 43.07 | 47.25 | 55.99 | 70.89 | 76.97 | 88.77 | 98.85 | 108.38 | 118.49 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $273.1M | $340.7M | $58.9M | $57.2M | $160.0M | $123.4M | $523.5M | $226.7M | $189.2M | $155.5M | $134.7M | |
| Marketable Securities | $0.00 | $0.00 | $255.2M | $222.5M | $437.4M | $625.3M | $669.1M | $685.5M | $412.3M | $294.4M | $241.3M | |
| Total Current Assets | $281.3M | $354.8M | $325.0M | $289.5M | $616.5M | $769.3M | $1.22B | $998.3M | $639.9M | $527.7M | $466.4M | |
| Total Assets | $299.0M | $376.2M | $347.3M | $334.3M | $676.3M | $1.29B | $1.52B | $1.30B | $1.19B | $842.1M | $758.8M | |
| Total Current Liabilities | $30.7M | $31.4M | $40.6M | $35.6M | $64.3M | $125.8M | $126.6M | $115.2M | $110.9M | $103.9M | $76.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $89.1M | $75.6M | $69.4M | $64.4M | $149.3M | $254.2M | $284.5M | $250.8M | $319.1M | $170.7M | $137.8M | |
| Stockholders' Equity | $209.8M | $300.6M | $277.9M | $269.9M | $527.1M | $1.04B | $1.24B | $1.05B | $872.0M | $671.4M | $620.9M | |
| Retained Earnings | $-53.6M | $-121.1M | $-201.0M | $-300.9M | $-435.1M | $-703.0M | $-1.18B | $-1.66B | $-2.18B | $-2.59B | $-2.69B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $36.1M | $-65.3M | $-61.3M | $-103.2M | $-49.9M | $-225.0M | $-333.3M | $-394.1M | $-348.9M | $-394.7M | $-363.2M | |
| Capital Expenditure | $-6.2M | $-10.1M | $-6.4M | $-6.8M | $-3.6M | $-12.8M | $-58.4M | $-14.0M | $-5.8M | $-1.1M | $-473.0K | |
| Free Cash Flow | $29.9M | $-75.4M | $-67.6M | $-110.0M | $-53.5M | $-237.8M | $-391.7M | $-408.1M | $-354.7M | $-395.9M | $-363.6M | |
| Investing Cash Flow | $-6.2M | $-10.1M | $-260.8M | $25.2M | $-214.5M | $-550.8M | $160.3M | $-31.3M | $125.6M | $228.0M | $200.0M | |
| Financing Cash Flow | $167.3M | $143.0M | $40.2M | $76.4M | $371.8M | $736.7M | $583.0M | $130.3M | $185.7M | $131.5M | $165.1M | |
| Issuance of Stock | $170.5M | $141.0M | $28.5M | $72.3M | $358.6M | $693.6M | $565.8M | $119.8M | $176.9M | $128.2M | $161.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.7M | $15.3M | $17.0M | $15.1M | $19.9M | $47.0M | $91.4M | $134.1M | $154.3M | $80.2M | $71.9M | |
| Net Change in Cash | $197.2M | $67.6M | $-281.8M | $-1.6M | $107.4M | $-39.1M | $410.0M | $-295.1M | $-37.6M | $-35.2M | $1.9M |
Dilution Tracker
Shares outstanding grew 67.1% over 5 years — significant dilution
Shares Outstanding
118M
5-Year Share Growth
+67.1%
Stock Issuance (TTM)
$161.7M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 22.22 | 36.01 | 43.07 | 47.25 | 55.99 | 70.89 | 76.97 | 88.77 | 98.85 | 108.38 | 118.49 | |
| YoY Change % | — | 62.0% | 19.6% | 9.7% | 18.5% | 26.6% | 8.6% | 15.3% | 11.4% | 9.6% | 9.3% | |
| Stock Issuance | $170.5M | $141.0M | $28.5M | $72.3M | $358.6M | $693.6M | $565.8M | $119.8M | $176.9M | $128.2M | $161.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.7M | $15.3M | $17.0M | $15.1M | $19.9M | $47.0M | $91.4M | $134.1M | $154.3M | $80.2M | $71.9M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | -195.2% | -266.3% | -298.6% | -246.8% | -235.5% | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% | -636.6% | |
| Net Margin % | -192.0% | -258.6% | -280.4% | -230.9% | -231.5% | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% | -597.0% | |
| EBITDA Margin % | -188.5% | -254.9% | -283.9% | -233.8% | -224.6% | -789.5% | -864.5% | -1395.8% | -905.3% | -628.1% | -612.9% | |
| FCF Margin % | 181.7% | -288.6% | -222.2% | -255.3% | -92.2% | -719.4% | -751.5% | -1124.9% | -612.8% | -585.0% | -550.2% | |
| ROE % | -33.5% | -26.5% | -29.5% | -36.3% | -33.7% | -34.2% | -41.7% | -42.1% | -54.0% | -53.5% | -55.8% | |
| ROA % | -16.6% | -20.0% | -23.6% | -29.2% | -26.6% | -27.2% | -33.7% | -34.1% | -41.7% | -40.6% | -44.7% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S24.22
Historical12.52 / 33.28 / 340.40
Industry Med.9.49
P/B2.76
Historical0.88 / 2.90 / 24.41
Industry Med.2.93
EV/EBITDA-4.17
Historical-64.57 / -5.81 / -0.57
Industry Med.13.02
EV/Revenue25.58
Historical3.22 / 22.48 / 345.73
Industry Med.8.59
P/FCF—
Historical5.00 / 5.96 / 8.61
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$5.16
Net Current Assets
$2.730
Median P/S Value
$20.10
Net-Net Working Capital
$2.03
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 17.67 | 26.51 | 19.31 | 16.09 | 52.51 | 253.73 | 51.54 | 74.55 | 19.90 | 14.41 | 24.22 | |
| PB Ratio | 2.25 | 2.71 | 2.14 | 2.73 | 6.84 | 8.47 | 2.46 | 2.70 | 1.36 | 1.56 | 2.76 | |
| EV/EBITDA | -6.41 | -7.12 | -3.25 | -4.71 | -23.37 | -31.16 | -4.39 | -4.03 | -1.52 | -1.62 | -4.17 | |
| EV/Revenue | 12.08 | 18.15 | 9.22 | 11.02 | 52.51 | 246.05 | 37.93 | 56.20 | 13.79 | 10.18 | 25.58 |
Analyst Estimates & Quality
Altman Z-Score
2.68
Grey Zone
Piotroski F-Score
4
Moderate
Beneish M-Score
-2.65
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $62.11M | $111.41M | $240.13M |
| Net Income | $-417.18M | $-399.14M | $-316.54M |
| EPS | -3.16 | -1.70 | -0.18 |
| Book Value per Share | 4.84 | 4.43 | 4.21 |
| Operating Cash Flow per Share | -2.80 | 2.48 | 13.05 |
| Operating CF | $-332.16M | $293.86M | $1,546.30M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| The development of gene editing-based therapies | $67.7M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $67.7M |